

**Original Research Article**

# **ANTI-ULCER MECHANISMS OF L-CYSTEINE IN MALE WISTAR RATS**

## **ABSTRACT**

**Aim:** to evaluate the effect of L-cysteine pretreatment on indomethacin induced ulceration in male wistar rats.

**Study design:** experimental animal study

**Place and Duration of study:** Department of Physiology (inflammation and Gastrointestinal secretion unit), College of Medicine, University of Ibadan, Nigeria, between January and July 2017.

**Methodology:** Fifty male wistar rats were used for this study and were randomly divided into two study groups of thirty five (25) animals each. The first sub-group was used for the anti-ulcer studies; antioxidant enzymes (SOD and MDA), Nitric oxide (NO), mean ulcer score and gastric blood flow (GBF), while the second sub-group was used for the gastric mucus secretion study. Each sub group was divided into five groups with five animals per group as follows: ulcer control, L-cysteine (100 mg/kg, 300 mg/kg and 500 mg/kg), cimetidine (50 mg/kg). Results were analyzed using ANOVA and reported as Mean  $\pm$  SEM. Values were considered significant at  $P=0.05$ .

**Results:** The results of this study showed that L-cysteine (100mg, 300mg and 500mg respectively) pretreatment significantly reduced mean ulcer score ( $9.5\pm1.9$ ;  $7.5\pm1.5$ ;  $4.5\pm0.9$ ), MDA level ( $7.2\pm0.23$ ;  $7.49\pm0.3$ ;  $6.54\pm0.55$ ) and increased SOD activity ( $10.69\pm0.1$ ;

10.12±0.29; 14.76±0.07) when compared with the mean ulcer score, MDA and SOD in the ulcer control group (39.5±7.9; 10.62±1.11; 5.02±0.74). Also, NO level (10.8±0.44; 10.37±0.18; 8.41±0.06), gastric mucus secretion (0.92±0.008; 0.94±0.001; 0.99±0.001) and GBF (2.08±0.02; 2.11±0.06; 2.11±0.01) were significantly ( $p<0.05$ ) higher in the L-cysteine pre-treated animals when compared with NO, mucus secretion and GBF in the ulcer control (7.86±0.09; 0.82±0.01).

**Conclusion:** This study shows that L-cysteine pre-treatment has anti-ulcer potential which might be mediated through increased antioxidant enzymes, increased mucus secretion and enhancing gastric blood flow. This will be of immense advantage in the treatment of peptic ulcer.

**Keywords:** L-cysteine, cimetidine, antioxidants, mucus secretion, anti-ulcer.

## 1. INTRODUCTION

Peptic ulcer, a common gastrointestinal disorder, is a multifactorial and complex disease that involves imbalance between gastric offensive factors (e.g. lipid peroxidation) and defensive mucosal factors e.g. antioxidant enzymes [1, 2]. However, diverse factors such as non-steroidal anti-inflammatory drugs (NSAIDs), stressful lifestyle, alcohol consumption, *Helicobacter pylori* (*H. pylori*) infection, smoking, and family history can contribute to its pathogenesis [3, 4]. NSAIDs such as indomethacin are commonly prescribed drugs for the treatment of pain and inflammation in rheumatic disorders and osteoarthritis [5] but are associated with peptic ulcer as their major complications. The mechanisms underlying the pathogenesis of NSAIDs-induced ulcers are complex and multifactorial. It involves both prostaglandin-dependent (through Cyclooxygenase inhibition) and prostaglandin-independent mechanisms. The independent mechanisms include inflammatory, immunogenic, genetic, and stress response pathways [6].

48 In an attempt to protect the gastric mucosa from ulceration, enhance ulcer healing and  
49 prevent ulcer recurrence, pharmacological control of gastric acid secretion has long  
50 represented a desirable goal. Thus, there is an increasing need to develop more potent  
51 therapeutic agents for the treatment of peptic ulcer and several experimental studies have  
52 shown the effectiveness of some nutrients and food supplements in the management of peptic  
53 ulcer.

54 L-cysteine is an essential amino acid that is ingested from diet to meet up the body's  
55 requirement and is majorly found in most dairy foods (e.g. milk, egg, meat and spices). L-  
56 cysteine contains sulfhydryl group and serve as a precursor of hydrogen sulphide [7].  
57 Hydrogen sulphide is a potent mediator of vascular smooth muscle relaxation, exhibit anti-  
58 inflammatory activities and contribute to gastric mucosal defense [8, 9]. It has also been  
59 shown to reduce the severity of non-steroidal anti-inflammatory drugs and also protective in a  
60 number of models of acute gastric injury, but the mechanism underlying this action is unclear  
61 [10]. Therefore, the present study aimed at evaluating the mechanisms of action of this amino  
62 acid in the prevention of peptic ulcer.

## 63 **2.0 MATERIALS AND METHODS**

### 64 **2.1 DRUGS AND CHEMICALS USED**

65 Cimetidine, Ulcertret-20 (Swiss pharma pvt.Ltd. 3709, GIDC, Phase IV, Vatva, Ahmedabad-  
66 382 445, Gujarat, India. Indomethacin, Omecet (Medibios Laboratories PVT Limited. J-76,  
67 M.I.D.C, Tarapur, Taluka-Palghar Dist, Thane-401 506, India), L-cysteine, (Solgar, Inc. 600  
68 Willow Tree Road, Leonia, NJ 07605 U.S.A. Sodium thiopental (Abbot Laboratories),  
69 Trichloroacetic acid (TCA), Thiobarbituric acid (TBA), Ellman reagent (5', 5' dithio-bis-2-  
70 nitrobenzoic acid), Sodium azide, 1-2, 4-dinitrobenzene.

### 71 **2.2 Experimental design**

72 Fifty adult male Wistar rats weighing 100-130 g were used for this study. The animals were  
73 obtained from Central Animal house, College of Medicine, University of Ibadan. The  
74 experimental animals were acclimatized for two weeks and were fed on rats' pellets and  
75 water given *ad libitum*. After the period of acclimatization, the experimental animals were  
76 divided into two groups each containing twenty-five animals and each group were subdivided  
77 into five groups containing five animals each and treated as follows; Group 1 (control) -  
78 normal rats that had access to clean water and rat pellets; Group 2- animals pre-treated with  
79 100 mg/kg body weight of L-cysteine; Group 3- animals pre-treated with 300 mg/kg body  
80 weight of L-cysteine; Group 4- animals- pre-treated with 500 mg/kg body weight of L-  
81 cysteine; group 5- animals pre-treated with 50 mg/kg body weight of cimetidine.  
82 The first sub-group was used for the anti-ulcer studies; antioxidant enzymes (SOD and  
83 MDA), Nitric oxide, Gastric blood flow and the mean ulcer score, while gastric mucus  
84 secretion study was performed with the second sub-group. All procedures used in this study  
85 conformed to the guidelines on the care and use of animals in research and teaching [11].

### 86 **2.3 Indomethacin Gastric Ulcer Induction**

87 Gastric ulcer was induced in the experimental animals using indomethacin at a dosage of 40  
88 mg/kg body weight in accordance with previously described method by [12]. Afterwards, the  
89 animals were sacrifice by cervical dislocation 4 hours after ulcer induction.

### 90 **2.4 Assessment of Ulcer Spots**

91 Macroscopic examination of the stomach was carried out and scored using the method  
92 described by [13] modified by [14]. Ulcer index was calculated using the formula.

93 
$$\text{Ulcer index} = \text{Mean Ulcer Score} \times \text{Number of animals in a group}/100$$

### 94 **2.5 Assay of Superoxide Dismutase (SOD)**

SOD activity was measured by assessing the inhibition of autoxidation of adrenaline at 30°C with the pH raised from 7.8-10.2 using the method described by [15].

## 2.6 Determination of lipid peroxidation

MDA (marker for oxidative stress) assessment was done according to the method of [16].

MDA which is the unit for lipid peroxidation is calculated in units/mg protein, using the formula:

$$\text{MDA (units/mg proteins)} = (\text{Absorbance} \times \text{Volume of mixture}) / (\text{E532nm} \times \text{Volume of sample} \times \text{mg protein}).$$

## 2.7 Gastric Mucus Secretion Study

This study was carried out using the spectrophotometry method described by [17]. The weight of dye was expressed over the weight of the stomach, to give the weight of mucus secreted.

Thus,

$$\text{Gastric mucus secretion (mg/g tissue)} = \frac{\text{Weight of dye (mg)}}{\text{Weight of stomach (g)}}$$

## 2.8 Determination on Nitric Oxide Levels

Nitrite was determined as an oxidation product and indicator of NO synthesis as described by [18]. The method is based on the addition of Griess reagent to the sample which converts nitrite into deep purple azo chromophore. The colour intensity was measured using a UV-visible spectrophotometer. Nitrite level was expressed as mol/g tissue.

## 2.9 DETERMINATION OF GASTRIC BLOOD FLOW

Gastric blood flow was measured as a component of abdominal aortic blood flow. Abdominal aortic blood flow was measured by placing an ultrasonic Doppler flow probe (Transonic# 11RB) around the abdominal aorta between the diaphragms and celiac artery.

119 Flow rates were obtained with the Transonic T206 Blood Flow Meter (Transonic Instrument,  
120 Ithaca, NY).

121 Animals were fasted, but not deprived of water for 24 hours before the onset of the  
122 experiment. 1 hour before ulcer induction, the test substance were administered to their  
123 respective group after which indomethacin was given to induced ulcer in all groups except  
124 group 1 (control group). Animals were anesthetized with ketamine (1ml/kg) intraperitoneal.  
125 A midline laparotomy was performed to expose the abdominal aorta for the placement of  
126 probe. The intestine of the rats was deflected to the right to expose the abdominal aorta.  
127 Adjacent fats were removed for proper acoustical coupling. The recorded blood flow was  
128 expressed in ml/min.


## 129 **2.10 Statistical Analysis**

130 Data were expressed as Mean  $\pm$  Standard Error of Mean (SEM). Statistical analysis was  
131 performed with Graph Pad Prism 5.0. Comparison between mean were done using one way  
132 analysis of variance (ANOVA) and differences between means were considered statistically  
133 significant at  $P=0.05$ .

## 134 **3. RESULTS**

### 135 **3.1 Effect of L-cysteine Pre-treatment on Gastric Mucus Secretion**

136 Animals pre-treated with various doses of L-cysteine showed significant increase in gastric  
137 mucus secretion when compared with the ulcer control group. The groups treated with the  
138 standard drug; cimetidine and 500 mg/kg L-cysteine showed the highest secretion of gastric  
139 mucus. There was also a dose-dependent increase in gastric mucus secretion in the L-cysteine  
140 treated group as shown in Fig 1.



141


142 Figure 1: Effect of Cysteine on mucus secretion in Indomethacin induced ulceration in rats.

143 \* $p < 0.05$ , \*\*  $p < 0.005$ , \*\*\*  $p < 0.0005$  when compared with ulcer control.

### 144 3.2 Effect of L-cysteine pre-treatment on antioxidant enzymes

#### 145 3.2.1 Superoxide dismutase

146 The level of superoxide dismutase obtained from this study are presented in Fig. 2. There was  
 147 a significant increase in super oxide dismutase level in all the L-cysteine and cimetidine pre-  
 148 treated animals when compared with the control.




149

150 Figure 2: Effect of L-cysteine on Superoxide Dismutase (SOD) in Indomethacin-induced  
 151 ulceration in rats. \*  $p < 0.05$ , \*\*  $p < 0.005$ , when compared with ulcer control.

### 152 3.2.2 Lipid peroxidation

153 Fig. 3 shows gastric mucosal malondialdehyde (MDA) levels recorded in L-cysteine pre-  
 154 treated animals. All the pre-treated animals showed significant decrease in lipid peroxidation  
 155 when compared to the animals in the ulcer control group.



156



Figure 3: Effect of Cysteine on Malondialdehyde (MDA) in Indomethacin induced ulceration

\* $p < 0.05$ , \*\* $p < 0.005$  when compared with ulcer control.

### 3.3 Effect of L-cysteine on Gastric Nitric Oxide Level

The results obtained from the nitric oxide study are presented in Fig. 4. In this study, pre-treatment with L-cysteine caused a significant increase in nitric oxide concentration similar with the standard drug cimetidine.





Figure 4: Effect of L-cysteine on Nitric Oxide activity in Indomethacin induced ulceration

\* $p < 0.05$  when compared with ulcer control.

### 3.4 Effect of L-cysteine pre-treatment on gastric blood flow in indomethacin induced ulceration in rats

The gastric blood flow was significantly increased in all the treated groups compare to the ulcer control group as shown in Fig. 5.



172

173 Figure 5: Effect of Cysteine on Gastric blood flow in indomethacin-induced ulceration.

174 \* $p < 0.05$  when compared with ulcer control.

### 175 3.5 Effect of L-cysteine Pre-treatment on Mean Ulcer Score

176 The mean ulcer score recorded in this study is presented in table 1. The ulcer control group  
 177 had a mean ulcer score of  $39.5 \pm 7.90 \text{ mm}^2$  which was significantly reduced in all the L-  
 178 cysteine treated groups in a dose-dependent manner.

179 Table 1: effect of L-cysteine pretreatment on mean ulcer score.

groups	Mean ulcer score ( $\text{mm}^2$ )
Control	$39.5 \pm 7.9$
L-cysteine (100 mg/kg)	$9.5 \pm 1.9^*$
L-cysteine (300 mg/kg)	$7.5 \pm 1.5^*$
L-cysteine (500 mg/kg)	$4.5 \pm 0.9^{**}$
Cimetidine	$7.0 \pm 1.4^*$

180 \* $p < 0.05$  when compared with ulcer control.

#### 4. DISCUSSION

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat musculoskeletal disorders, and are used almost routinely long term by patients with rheumatoid arthritis but has been associated with development of gastric ulcers [19]. It has been demonstrated that NSAIDs (e.g. indomethacin) cause peptic ulceration by a combination of direct effects in the mucous barrier and by local and systemic inhibition of the prostaglandin system. The inhibition of endogenous prostaglandins (PGs) and related compounds, decreases gastric mucosal blood flow, and carbonate synthesis as well as increasing susceptibility to mucosal injury and gastric ulceration [20, 21]. In addition, sequel to the acidic nature of indomethacin [22], it enhances lipid peroxidation and generation of free radicals in the gastric mucosa [23] thereby leading to oxidative damage [24]. Thus, NSAIDs given orally or systemically will cause damage to gastric protective mechanisms, allowing gastric acid to penetrate to submucous structures and thus cause ulceration. Therefore, strategies to protect the gastric mucosa from this offensive agent has been of immense interest to various scientists.

The importance of increased mucus strength and quantity in protecting the regenerating gastric epithelium has been established [25, 26]. Gastric mucus is the first protective barrier in the gastric epithelium that prevents the actions of free radical on the stomach mucosal [27] which could lead to the formation of ulcers [28]. Hydrophobicity play a significant role in protecting the gastric membrane against noxious agents in the lumen [29] as the protective property of the mucus barrier depends not only on the gel structure but also on the amount or thickness of the layer covering the mucosal surface [30]. In this present study, there was an increase in the gastric mucus secretion in the group of animal pre-treated with L-cysteine, which implies that L-cysteine has a promising potential in ameliorating indomethacin- induce peptic ulcer. This report is in agreement with the earlier work carried out by [31], where it was reported that gastric mucus secretion increased in the gastric mucosa of animals treated

with aqueous extract of *Eremomastax speciose* against indomethacin-induced ulceration. Allen and Flemstrom reported that an increase in the gastric mucus secretion in stomach confers double protection on the gastric mucosal as it prevents physical damage by acting as a lubricant and chemical damage by sequestering bicarbonate and forming a pH gradient against the proteolytic and acid nature of gastric juice [32].

It has been reported that biochemical with antioxidant properties exerts gastroprotective function [33]. Studies have demonstrated that these compounds can scavenge free radicals and are also involve in inhibition of lipid peroxidation, mucus production, decrease of histamine levels and inhibition of gastric acid secretion [34, 35]. Studies have demonstrated that L-cysteine supplementation in rats reduces reactive oxygen species (ROS) thereby demonstrating its antioxidant property [36, 37] and also contain sulfhydryl group which are precursors of hydrogen sulfide [38] that mediate various biological functions.

In this study, the antioxidant activity of L-cysteine against indomethacin-induced ulcer in rats was observed to determine the possible mechanism of action of this amino acid. L-cysteine mediate its protective role against indomethacin-induced ulcer by reducing the level of malondialdehyde (marker for oxidative stress) and also enhancing the superoxide dismutase activity (antioxidant enzyme). Antioxidant compounds are able to protect the gastric mucosa by binding to acetylcholine muscarinic receptors inhibiting acid secretion [39] and attenuating blood flow, thereby diminishing the hemorrhagic lesions [40].

In this study, it was confirmed that the standard drug cimetidine caused a significant increase in nitric oxide. Similar result was recorded when the animals were pre-treated with L-cysteine compared with the control group. Nitric oxide is one of the most important defensive endogenous agents in the gastric mucosa [41]. It is essentially important in the regulation of gastric blood flow and also increases mucus secretion in the gastric mucosa [42]. It inhibits

the activation of leukocytes within the microcirculation, and inhibits the inherent release of reactive oxygen metabolites and proteases [43]. On the other hand, suppression of NO production has been reported to delay healing process and this effect was accompanied by a decrease in the gastric blood flow, mucosal growth parameters and attenuated angiogenic response [44]. Also, data obtained from in vitro and in vivo studies suggested that nitric oxide exerts an anti-apoptotic effect on rat gastrointestinal mucosal cells [45]. In addition, L-cysteine contains sulfhydryl group (SH) and serve as a precursor of hydrogen sulphide. Hydrogen sulphide is a potent mediator of vascular smooth muscle relaxation, exhibit anti-inflammatory activities and contribute to gastric mucosal defense [46]. The SH groups are also responsible for increasing the production of and maintaining mucus stability, through the disulfide bridges, and are involved in maintaining gastric integrity, thereby limiting the production of free radicals involved in tissue damage [47]. The relatively high concentrations of SH have been implicated as in gastroprotection [48].

In this study, pre-treatment with L-cysteine caused a significant reduction in the mean ulcer score. The percentage ulcer inhibition in animal pre-treated with L-cysteine were comparable to the standard drug cimetidine and appears to be dose-dependent. Cimetidine is a histamine H<sub>2</sub> receptor antagonist which markedly inhibits gastric acid secretion [49, 50]. This supports the earlier study that cimetidine significantly reduces the effect of NSAIDs-induced peptic ulcer [51]. Thus, L-cysteine could also exert its anti-ulcerogenic effect via the inhibition of H<sub>2</sub> receptors in the gastric epithelia cells.

Despite the potent therapeutic effect of non-steroidal anti-inflammatory drugs (NSAIDs), it has been classically established that NSAIDs, such as indomethacin, significantly reduces prostaglandin levels and blood flow to gastric mucosa and thus are considered ulcerogenic agents in long-term use [52]. It is therefore important to assess the gastroprotective effects of

different doses of L- cysteine against indomethacin-induced gastric ulcer. As shown in Fig. 5, pre-treatment with L-cysteine caused a significant increase in gastric blood flow compared to the vehicle-treated ulcerated group. The increase in gastric blood flow facilitated by L-cysteine contributes to protection by supplying the mucosa with oxygen and  $\text{HCO}_3^-$ , and by removing  $\text{H}^+$  and toxic agents diffusing from the lumen into the mucosa. Thus, the results showed that L-cysteine has anti-ulcer potential against different ulcerogenic agents which may be due to the high sulfhydryl content of this amino acid.

## 5. CONCLUSION

The result from this study shows that L-cysteine possess antiulcer activities which can be attributed to its antioxidant properties, its ability to enhance gastric mucus secretion as well as its sulfhydryl content. L-cysteine which is usually taken as a supplement might therefore be beneficial to people with peptic ulcer disease.

## 6. REFERENCES

1. Malfertheiner P, Francis KL, Kenneth EL. Peptic ulcer disease. *The Lancet*. 2009; 374(9699):1449-61.
2. Venkateswara C, Venkataramana K. A pharmacological review on natural antiulcer agents. *Journal of pharmacognosy*. 2013; 4(3):1118-31.
3. Drini M. Peptic ulcer disease and non-steroidal anti-inflammatory drugs. *Australian Prescriber* 2017; 40(3): 91–93.
4. Schubert ML. Gastric secretion. *Current Opinion in Gastroenterology* 2014; 30(6):578–582.
5. Yadav SK, Adhikary B, Bandyopadhyay SK, Chattopadhyay S. Inhibition of TNF- $\alpha$ , and NF-kappa B and JNK pathways accounts for the prophylactic action of the

- 277 natural phenolic, allylpyrocatechol against indomethacin gastropathy. *Biochimica et*  
278 *Biophysica Acta* 2013; 1830(6):3776-3786.
- 279 6. Ohyama, K, Shiokawa A, Ito K, Masuyama R, Ichibangase T, Kishikawa N, et al.  
280 Toxicoproteomic analysis of a mouse model of nonsteroidal anti-inflammatory drug-  
281 induced gastric ulcers. *Biochem. Biophys. Res. Commun* 2012; 420(1): 210-215.
- 282 7. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace J L. Hydrogen  
283 sulfide is an endogenous modulator of leukocyte-mediated inflammation. *FASEB*  
284 *Journal* 2006; 20; 2118–2120.
- 285 8. Bhatia M, Sidhapuriwala J, Moomhala SM, Moore PK. Hydrogen sulphide is a  
286 mediator of carrageenan-induced hind paw oedema in the rat. *Br J Pharmacol* 2005;  
287 145(2): 141–144.
- 288 9. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second  
289 hundred years. *Gastroenterology* 1997; 112, 1000–1016.
- 290 10. Atalay F, Odabasoglu F, Halici M, Cadirci E, Aydin O, Halici Z, Cakir A. N-Acetyl  
291 Cysteine Has Both Gastro-Protective and Anti-Inflammatory Effects in Experimental  
292 Rat Models: Its Gastro-Protective Effect Is Related to Its In Vivo and In Vitro  
293 Antioxidant Properties. *Journal of Cellular Biochemistry* 2015; 117(2): 308–319.
- 294 11. National Institute of Health. NIH consensus Development program. NIH statement  
295 1996; 14(1):1-38.
- 296 12. Oluwole FS, Bolarinwa AF. Experimental peptic ulceration during oestrous cycle. *Nig.*  
297 *J. Physiol Sci.* 1991; 7(1):18-21.
- 298 13. Alphin RS, Ward JW. Actions of Hexopyrronium Bromide on gastric secretion in dogs  
299 and Ulceration in rats. *Biomed. Environ Sci.* 1967; 6(1):488-95.
- 300 14. Elegbe RA, Bambgose SOA. Protective dietary factors in experimental ulceration-  
301 Studies on some Nigerian cereal and tubers. *Postgrad. Med.* 1976; 52(607):258- 63.

- 302 15. Misra HP, Fridovich I. The role of superoxide anion in the antioxidation of epinephrine  
303 and a simple assay for superoxide dismutase. *J. Biol Chem.* 1972; 25(10):3170-75.
- 304 16. Varshney R, Kale RK. Effects of calmodulin antagonist on radiation induced lipid  
305 peroxidation in microsomes. *Int J Radiat Biol.* 1990; 58(5):733-43.
- 306 17. Corney IN, Dhuley JN, Naik SR. Protection by rhinax in various models of ulceration in  
307 rats. *J. Ethnopharmacol.* 1998; 197463: 219-2125.
- 308 18. Moshage H, Kok B, Huiezena JR, Jansen PL. Nitrite and nitrate determinations in  
309 plasma: A critical evaluation. *Clin Chem.* 1995; 41(6):892-96.
- 310 19. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy. *Arch Intern*  
311 *Med* 1987; 147(2): 2093-100.
- 312 20. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of  
313 cyclooxygenase inhibition and gastric hyper motility. *World J Gastroenterol.* 2012;  
314 14(18):2147-60.
- 315 21. Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current Perspectives in  
316 NSAID-Induced Gastropathy. *Mediators Inflamm.* 2013; 1-11.
- 317 22. Tarnawski A, Brzozowski T, Sarfeh IJ, Krause WJ, Ulich TR, Gergely H, et al.  
318 Prostaglandin protection of human isolated gastric glands against indomethacin and  
319 ethanol injury. Evidence for direct cellular action of prostaglandin. *J Clin Invest.* 1988;  
320 81(4): 1081–1089.
- 321 23. Suleyman H, Albayrak A, Bilici M, Cadirci E, Halici Z. Different mechanisms in  
322 formation and prevention of indomethacin-induced gastric ulcers. *Inflammation* 2010;  
323 33:224-34.
- 324 24. Potrich FB, Allemand A, Silva LM, Dos Santos AC, Baggio CH, Freitas  
325 CS. Antiulcerogenic activity of hydroalcoholic extract of *Achillea millefolium* L:  
326 Involvement of the antioxidant system. *J Ethnopharmacol* 2010; 130(1):85-92.



- 327 25. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench  
328 to bedside, *Gastroenterology* 2008; 135(1): 41–60.
- 329 26. Polo CM, Moraes TM, Pellizzon CH, Marques MMO, Rocha LRM, Hiruma-Lima CA.  
330 Gastric ulcers in middle-aged rats: the healing effect of essential oil from citrus  
331 aurantium L. (Rutaceae), *Evidence-Based Complementary and Alternative Medicine*  
332 2012; 51(8): 1-8.
- 333 27. Gupta D, Du Y, Piluek J, Jakub AM, Buela KA, Abbott A, et al. Pyruvate ameliorates  
334 endotoxin-induced corneal inflammation. *Investig. Ophthalmol. Vis. Sci.* 2012;  
335 53(10):6589–99.
- 336 28. Yandrapu H, Sarosiek J. Protective factors of the gastric and duodenal mucosa: an  
337 overview, *Current Gastroenterology Reports* 2015; 17(24): 1-8.
- 338 29. Asante M, Ahmed H, Patel P, Davis T, Finlayson C, Mendall M, Northfield T. Gastric  
339 mucosal hydrophobicity in duodenal ulceration: role of *Helicobacter pylori* infection  
340 density and mucus lipids, *Gastroenterology* 1997; 113(2): 449–454.
- 341 30. Penissi A, Piezzi R. Effect of dehydroleucodine on mucus production. A quantitative  
342 study. *Digestive Diseases and Sciences.* 1999; 44(4):708-12.
- 343 31. Amang AP, Mezui C, Siwe GT, Emakoua J, Mbah G, Nkwengoua EZ, et al. Healing  
344 and Antisecretory Effects of Aqueous Extract of *Eremomastax speciosa* (Acanthaceae)  
345 on Unhealed Gastric Ulcers. *Biomed Res International.* 2017:1924320: 1-11.
- 346 32. Allen A, Flemstrom G. Gastroduodenal mucus bicarbonate barrier: protection against  
347 acid and pepsin,” *American Journal of Physiology-Cell Physiology* 2005; 288(1):C1–  
348 C19.
- 349 33. Alvarez-Suarez JM, Dekanski D, Ristić S, Radonjić NV, Petronijević ND, Giampieri F,  
350 et al. Strawberry Polyphenols Attenuate Ethanol-Induced Gastric Lesions in Rats by

- 351           Activation of Antioxidant Enzymes and Attenuation of MDA Increase. PLoS One.  
352           2011; 6(10):1-11.
- 353   34.   Priya G, Parminder N, Jaspreet S. Oxidative stress induced ulcer protected by natural  
354           antioxidants: a review. International research journal of pharmacy 2012; 3(5): 76-81.
- 355   35.   Repetto MG, Llesuy SF. Antioxidant properties of natural compounds used in popular  
356           medicine for gastric ulcers. Braz J Med Biol Res, May 2002; 35(5):523-534.
- 357   36.   Pravina P.   Cysteine –master antioxidant. International journal of pharmaceutical,  
358           chemical and biological sciences. IJPCBS 2013; 3(1):143-149.
- 359   37.   Shimamoto K, Hayashi H, Taniai E, Morita R, Imaoka M, Ishii Y, et al. Antioxidant N-  
360           acetyl-L-cysteine (NAC) supplementation reduces reactive oxygen species (ROS)-  
361           mediated hepatocellular tumor promotion of indole-3-carbinol (I3C) in rats. J Toxicol  
362           Sci. 2011; 36(6):775-86.
- 363   38.   Shibuya N, Koike S, Tanaka M, Ishigami-Yuasa M, Kimura Y, Ogasawara Y, et al. A  
364           novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian  
365           cells. Nature Commun 2013; 4:1-7.
- 366   39.   Toma, W, Hirumu-Lima CA, Guerrero RO, Souza AR.   Preliminary studies on  
367           Mammea Americana L (Guttiferae) bark/latex extract point to an effective anti-ulcer  
368           effect on gastric ulcer models in mice. Phytomedicine 2005; 12(1): 345-50.
- 369   40.   O'Brien P, Carrasco-Pozo C, Speisky H. Boldine and its antioxidant or health-  
370           promoting properties. Chem Biol Interact. 2006; 159(1):1-17.
- 371   41.   El-Abhar HS. Coenzyme Q10: a novel gastroprotective effect via modulation of  
372           vascular permeability, prostaglandin E2, nitric oxide and redox status in indomethacin-  
373           induced gastric ulcer model. European Journal of Pharmacology 2010; 649(1): 314–  
374           319, 2010.

- 375 42. Kwiecień S, Brzozowski T, Konturek PCH, Konturek SJ. The role of reactive oxygen  
376 species in action of nitric oxide-donors on stress-induced gastric mucosal lesions.  
377 Journal of physiology and pharmacology 2002; 53(4): 761-773.
- 378 43. Niv Y, Banić M. Gastric barrier function and toxic damage, Digestive Diseases 2014;  
379 32(3): 235–242.
- 380 44. Konturek SJ, Brzozowski T, Majka J, PytkoPolonczyk J, Stachura J. Inhibition of nitric  
381 oxide synthase delays the healing of chronic gastric ulcers. EurJ Pharmacol 1993;  
382 239:215- 217.
- 383 45. Kochar NI, Chandewal AV, Bakal RL, Kochar PN. Nitric Oxide and the  
384 Gastrointestinal Tract. International Journal of Pharmacology 2011; 7 (1):  
385 31-39.
- 386 46. Wallace JL, Ferraz JGP, Muscara NM. Hydrogen Sulfide: An Endogenous Mediator of  
387 Resolution of Inflammation and Injury. Antioxid Redox Signal. 2012; 17(1): 58–67.
- 388 47. Caldas GFR, Oliveira ARD, Araújo AV, Lafayette SSL, Albuquerque GS, Silva-Neto  
389 JC, et al. Gastroprotective mechanisms of the monoterpene 1,8-cineole  
390 (eucalyptol) PLoS One 2015; 10(8): 1-17.
- 391 48. Zakaria ZA, Balan T, Azemi AK. Mechanism(s) of action underlying the  
392 gastroprotective effect of ethyl acetate fraction obtained from the crude methanolic  
393 leaves extract of *Muntingia calabura*,” BMC Complementary and Alternative Medicine  
394 2016: 16(1): 78-83.
- 395 49. Pounder RE, Williams JG, Russell CG. Inhibition of food stimulated gastric acid  
396 secretion by cimetidine. Gut 1976; 17(3):161-168.
- 397 50. Richardson CT, Walsh JH, Hicks MI. The effect of cimetidine, a new histamine H2-  
398 receptor antagonist, on meal-stimulated acid secretion, serum gastrin, and gastric  
399 emptying in patients with duodenal ulcer, Gastroenterology 1976; 71(1):19-23.

- 400 51. Davies J, Collins AJ, Dixonu AJ. The influence of cimetidine on peptic ulcer in patients  
401 with arthritis taking anti-inflammatory drugs. British Journal of Rheumatology 1986;  
402 25(1):54-58.
- 403 52. Mózsik G. Gastric cytoprotection 30 years after its discovery by André Robert: a  
404 personal perspective. Inflammopharmacology. 2010; 18(5):209-21.